Sai Life Sciences Limited has informed the Exchange regarding 'Disclosure of Key Performance Indicators under SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018'.
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Life Sciences Limited has disclosed detailed Key Performance Indicators (KPIs) covering FY2022 to FY2026 along with half-year data. The company showed strong consistent growth with revenue rising from ₹8,696 million to ₹21,925 million over four years. EBITDA grew from ₹1,311 million to ₹6,529 million, while PAT improved dramatically from ₹62 million to ₹3,489 million. EBITDA margin expanded from 15.07% to 29.78%, and PAT margin improved from 0.72% to 15.91%. Return on Capital Employed improved from 3.21% to 18.23%. The company is virtually debt-free with Net Debt/EBITDA at just 0.04x. The KPIs were verified by chartered accountants Bashey & Joshi. This disclosure is required under SEBI ICDR regulations, typically in connection with a capital raise.
The strong and consistent improvement across all financial metrics makes this company an attractive candidate for any upcoming equity offering. The high-quality financial performance demonstrated here could support a well-valued IPO or follow-on offer.